Top

Published in:

01-08-2005 | Review Article

Pharmacological Management of Nasal Polyposis

Authors: Prof. Dr Claus Bachert, Jean-Baptiste Watelet, Philippe Gevaert, Paul Van Cauwenberge

Published in: Drugs | Issue 11/2005

Abstract

Nasal polyposis affects nearly 4% of the total population in Western countries, and presents a real challenge to the physician because of its severity, chronicity and recurrence rate. Characteristic histomorphological features of polyps are an eosinophilic inflammation and the destruction of connective tissue; recent research has focused on cytokines, chemokines, growth factors and metalloproteinases to explain these features, as the aetiology of nasal polyposis remains largely unclear. Currently, topical and systemic corticosteroids are first-choice drug therapy approaches, and good evidence from controlled trials is available for topical, but not for systemic, corticosteroid therapy. Surgery is indicated if adequate drug treatment fails, which often needs to be maintained after surgery. There is limited experience for other drugs, such as antihistamines, leukotriene antagonists and frusemide (furosemide), which may be added to corticosteroid therapy in selected patients. Aspirin (acetylsalicylic acid) desensitisation may be a therapeutic option for patients who do not respond to corticosteroids or surgery. Recently, antibiotics such as macrolides have been suggested to have therapeutic activity based on their anti-inflammatory properties but large-scale controlled trials are lacking. New approaches are currently evolving, specifically targeting eosinophilic recruitment (chemokine receptor 3, eotaxin) and inflammation (interleukin-4, -5, -13), immunoglobulin-E, or tissue remodeling by reducing the activity of metalloproteinases.

This review summarises current knowledge on pathogenesis as well as established and future approaches in the pharmacological management of bilateral eosinophilic nasal polyposis.

Bachert C, Van Cauwenberge P. Nasal polyposis and sinusitis. In: Adkinson NF, Yunginger JW, Busse WW, et al., editors. Allergy: principles and practice. 6th ed. St Louis (MO): Mos-by, 2003: 1421–36

Hedman J, Kaprio J, Poussa T, et al. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol 1999; 28(4): 717–22PubMedCrossRef

Larsen PL, Tingsgaard PK, Harcourt J, et al. Nasal polyps and their relation to polyps/hypertrophic polypoid mucosa in the paranasal sinuses: a macro-, endo-, and microscopic study of autopsy materials. Am J Rhinol 1998; 12(1): 45–51PubMedCrossRef

Mygind N. Nasal polyposis. J Allergy Clin Immunol 1990; 86(6): 827–9PubMedCrossRef

Settipane GA. Epidemiology of nasal polyps. Allergy Asthma Proc 1996; 17(5): 231–6PubMedCrossRef

Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis and management. J Allergy Clin Immunol 1999; 104(1): 5–13PubMedCrossRef

Drake-Lee AB, Lowe D, Swanston A, et al. Clinical profile and recurrence of nasal polyps. J Laryngol Otol 1984; 98: 783–93PubMedCrossRef

Mygind N, Dahl R, Bachert C. Nasal polyposis, eosinophil dominated inflammation, and allergy. Thorax 2000; 55 Suppl. 2: S79–83PubMedCrossRef

Bachert C, Wagenmann M, Rudack C, et al. The role of cytokines in infectious sinusitis and nasal polyposis. Allergy 1998; 53(1): 2–13PubMedCrossRef

10.

Bachert C, Gevaert P, Holtappels G, et al. Total and specific IgE in nasal polyps is related to local eosinophilic inflammation. J Allergy Clin Immunol 2001; 107(4): 607–14PubMedCrossRef

11.

Bachert C, Gevaert P, Van Cauwenberge P. Staphylococcus aureus enterotoxins: a key in airway disease? Allergy 2002; 57(6): 480–7PubMedCrossRef

12.

Ponikau JU, Sherds DA, Kern EB, et al. The diagnosis and incidence of allergic fungal sinusitis. Mayo Clin Proc 1999; 74(9): 877–84PubMedCrossRef

13.

Ponikau JU, Sherris DA, Kita H, et al. Intranasal antifungal treatment in 51 patients with chronic rhinosinusitis. J Allergy Clin Immunol 2002; 110(6): 862–6PubMedCrossRef

14.

Herz U, Ruckert R, Wollenhaupt K, et al. Airway exposure to bacterial superantigen (SEB) induces lymphocyte-dependent airway inflammation associated with increased airway responsiveness: a model for non-allergic asthma. Eur J Immunol 1999; 29(3): 1021–31PubMedCrossRef

15.

Hauk PJ, Hamid QA, Chrousos GP, et al. Induction of corticosteroid insensitivity in human PBMCs by microbial superan-tigens. J Allergy Clin Immunol 2000; 105(4): 782–7PubMedCrossRef

16.

Bachert C, Gevaert P, Holtappels G, et al. Nasal polyposis: from cytokines to growth. Am J Rhinol 2000; 14(5): 279–90PubMedCrossRef

17.

Tos M, Sasaki Y, Ohnishi M, et al. Pathogenesis of nasal polyps. Rhinol Suppl 1992; 14: 181–5

18.

Bachert C, Wagenmann M, Hauser U, et al. IL-5 is upregulated in human nasal polyp tissue. J Allergy Clin Immunol 1997; 99(6): 837–42PubMedCrossRef

19.

Hamilos DL, Leung DY, Wood R, et al. Chronic hyperplastic sinusitis: association of tissue eosinophilia with mRNA expression of granulocyte-macrophage colony-stimulating factor and interleukin-3. J Allergy Clin Immunol 1993; 92(1): 39–48PubMedCrossRef

20.

Mullol J, Xaubet A, Gaya A, et al. Cytokine gene expression and release from epithelial cells: a comparison study between healthy nasal mucosa and nasal polyps. Clin Exp Allergy 1995; 25(7): 607–15PubMedCrossRef

21.

Ohno I, Lea R, Finotto S, et al. Granulocyte/macrophage colony-stimulating factor (GM-CSF) gene expression by eosinophils in nasal polyposis. Am J Respir Cell Mol Biol 1991; 5(6): 505–10PubMed

22.

Hamilos DL, Leung DY, Wood R, et al. Evidence for distinct cytokine expression in allergic versus nonallergic chronic sinusitis. J Allergy Clin Immunol 1995; 96(4): 537–44PubMedCrossRef

23.

Elovic A, Wong DT, Weller PF, et al. Expression of transforming growth factors-alpha and beta 1 messenger RNA and product by eosinophils in nasal polyps. J Allergy Clin Immunol 1994; 93(5): 864–9PubMedCrossRef

24.

Lee CH, Rhee CS, Ming YG. Cytokine gene expression in nasal polyps. Ann Otol Rhinol Laryngol 1998; 107(8): 665–70PubMed

25.

Simon HU, Yousefi S, Schranz C, et al. Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. J Immunol 1997; 158(8): 3902–8PubMed

26.

Gevaert P, Bachert C, Holtappels G, et al. Enhanced soluble interleukin 5 receptor alpha expression in nasal polyposis. Allergy 2003; 58(5): 371–9PubMedCrossRef

27.

Alam R, Forsythe P, Stafford S, et al. Transforming growth factor beta abrogates the effects of hematopoietins on eosinophils and induces their apoptosis. J Exp Med 1994; 179(3): 1041–5PubMedCrossRef

28.

Watelet JB, Claeys C, Perez-Novo C, et al. TGF-beta 1 in remodeling of nasal tissue: differences between chronic rhinosinusitis and nasal polyposis. Am J Rhinol 2004 Sep–Oct; 18(5): 267–72PubMed

29.

Sanchez-Segura A, Brieva JA, Rodriguez C. T lymphocytes that infiltrate nasal polyps have a specialized phenotype and produce a mixed TH1/TH2 pattern of cytokines. J Allergy Clin Immunol 1998; 102(6): 953–60PubMedCrossRef

30.

Nonaka M, Nonaka R, Woolley K, et al. Distinct immunohistochemical localization of IL-4 in human inflamed airway tissues. IL-4 is localized to eosinophils in vivo and is released by peripheral blood eosinophils. J Immunol 1995; 155(6): 3234–44

31.

Bartels J, Maune S, Meyer JE, et al. Increased eotaxin-mRNA expression in non-atopic and atopic nasal polyps: comparison to RANTES and MCP-3 expression. Rhinology 1997; 35(4): 171–4PubMed

32.

Jahnsen FL, Haye R, Gran E, et al. Glucocorticosteroids inhibit mRNA expression for eotaxin, eotaxin-2, and monocyte-chemotactic protein-4 in human airway inflammation with eosinophilia. J Immunol 1999; 163(3): 1545–51PubMed

33.

Symon FA, Walsh GM, Watson SR, et al. Eosinophil adhesion to nasal polyp endothelium is P-selectin-dependent. J Exp Med 1994; 180(1): 371–6PubMedCrossRef

34.

Jahnsen FL, Haraldsen G, Aanesen JP, et al. Eosinophil infiltration is related to increased expression of vascular cell adhesion molecule-1 in nasal polyps. Am J Respir Cell Mol Biol 1995; 12(6): 624–32PubMed

35.

Braun H, Stammberger H, Buzina W, et al. Incidence and detection of fungi and eosinophilic granulocytes in chronic rhinosinusitis. Laryngorhinootologie. 2003 May; 82(5): 330–40PubMedCrossRef

36.

Watelet JB, Bachert C, Claeys C, et al. Matrix metal-loproteinases MMP-7, MMP-9 and their tissue inhibitor TIMP-1: expression in chronic sinusitis versus nasal polyposis. Allergy 2004 Jan; 59(1): 54–60PubMedCrossRef

37.

Vento SI, Ertama LO, Hytonen ML, et al. Nasal polyposis: clinical course during 20 years. Ann Allergy Asthma Immunol 2000; 85(3): 209–14PubMedCrossRef

38.

Blomqvist EH, Lundblad L, Anggard A, et al. A randomized controlled study evaluating medical treatment versus surgical treatment in addition to medical treatment of nasal polyposis. J Allergy Clin Immunol 2001; 107(2): 224–8PubMedCrossRef

39.

Adcock IM, Gilbey T, Gelder CM, et al. Glucocorticoid receptor localization in normal and asthmatic lung. Am J Respir Crit Care Med 1996; 154(3): 771–82PubMed

40.

Beato M. Gene regulation by steroid hormones. Cell 1989; 56(3): 335–44PubMedCrossRef

41.

Cato AC, Wade E. Molecular mechanisms of anti-inflammatory action of glucocorticoids. Bioassays 1996; 18(5): 371–8CrossRef

42.

Rudack C, Bachert C, Stell W. Effect of prednisolone on cytokine synthesis in nasal polyps. J Interferon Cytokine Res 1999; 19(9): 1031–5PubMedCrossRef

43.

Bolard F, Gosset P, Lamblin C, et al. Cell and cytokine profiles in nasal secretions from patients with nasal polyposis: effects of topical steroids and surgical treatment. Allergy 2001; 56(4): 333–8PubMedCrossRef

44.

Bachert C, Gevaert P. Effects of intranasal corticosteroids on release of cytokines and inflammatory mediators. Allergy 1999; 54 Suppl. 57: 116–23CrossRef

45.

Henriksson G, Norlander T, Forsgren J, et al. Effects of topical budesonide treatment on glucocorticoid receptor mRNA down-regulation and cytokine patterns in nasal polyps. Am J Rhinol 2001; 15(1): 1–8PubMedCrossRef

46.

Lemjabbar H, Gosset P, Lechapt-Zalcman E, et al. Overexpression of alveolar macrophage gelatinase B (MMP-9) in patients with idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 1999; 20(20): 903–13PubMed

47.

Naclerio RM, Adkinson Jr N, Creticos PS, et al. Intranasal steroids inhibit seasonal increases in ragweed-specific immunoglobulin E antibodies. J Allergy Clin Immunol 1993; 92(5): 717–21PubMedCrossRef

48.

Godthelp T, Fokkens WJ, Kleinjan A, et al. Antigen presenting cells in the nasal mucosa of patients with allergic rhinitis during allergen provocation. Clin Exp Allergy 1996; 26(6): 677–88PubMedCrossRef

49.

van Camp C, Clement PA. Results of oral steroid treatment in nasal polyposis. Rhinology 1994; 32(1): 5–9PubMed

50.

Schaaf MJ, Cidlowski JA. Molecular mechanisms of glucocorticoid action and resistance. J Steroid Biochem Mol Biol 2002; 83(1–5): 37–48PubMedCrossRef

51.

Hamilos DL, Leung DY, Muro S, et al. GRbeta expression in nasal polyp inflammatory cells and its relationship to the anti-inflammatory effects of intranasal fluticasone. J Allergy Clin Immunol. 2001; 108(1): 59–68PubMedCrossRef

52.

Badia L, Lund V. Topical corticosteroids in nasal polyposis. Drugs 2001; 61(5): 573–8PubMedCrossRef

53.

Filiaci F, Passali D, Puxeddu R, et al. A randomized controlled trial showing efficacy of once daily intranasal budesonide in nasal polyposis. Rhinology 2000; 38(4): 185–90PubMed

54.

Lund VJ, Flood J, Sykes AP, et al. Effect of fluticasone in severe polyposis. Arch Otolaryngol Head Neck Surg 1998; 124(5): 513–8PubMed

55.

Tos M, Svendstrup F, Arndal H, et al. Efficacy of an aqueous and a powder formulation of nasal budesonide compared in patients with nasal polyps. Am J Rhinol 1998; 12(3): 183–9PubMedCrossRef

56.

Holmberg K, Juliusson S, Balder B, et al. Fluticasone propionate aqueous nasal spray in the treatment of nasal polyposis. Ann Allergy Asthma Immunol 1997; 78(3): 270–6PubMedCrossRef

57.

Keith P, Nieminen J, Hollingworth K, et al. Efficacy and tolerability of fluticasone propionate nasal drops 400 microgram once daily compared with placebo for the treatment of bilateral polyposis in adults. Clin Exp Allergy 2000; 30(10): 1460–8PubMedCrossRef

58.

Lildholdt T, Rundcrantz H, Bende M, et al. Glucocorticoid treatment for nasal polyps: the use of topical budesonide powder, intramuscular betamethasone, and surgical treatment. Arch Otolaryngol Head Neck Surg 1997; 123(6): 595–600PubMedCrossRef

59.

Lildholdt T, Rundcrantz H, Lindquist N. Efficacy of topical corticosteroids powder for nasal polyps: a double-blind placebo-controlled study of budesonide. Clin Otolaryngol 1995; 20(1): 26–30PubMedCrossRef

60.

Chalton R, Mackay I, Wilson R, et al. Double-blind, placebo-controlled trial of beclomethasone nasal drops for nasal polyposis. BMJ (Clin Res Ed) 1985; 291(6498): 788CrossRef

61.

Hartwig S, Linden M, Laurent C, et al. Budesonide nasal spray as prophylactic treatment after polypectomy (a double blind clinical trial). J Laryngol Otol 1988; 102(2): 148–51PubMedCrossRef

62.

Virolainen E, Puhakka H. The effect of intranasal beclomethasone dipropionate on the recurrence of nasal polyps after ethmoidectomy. Rhinology 1980; 18(1): 9–18PubMed

63.

Krouse HA, Phung ND, Klaustermeyer WB. Intranasal beclomethasone in severe rhinosinusitis and nasal polyps. Ann Allergy 1983; 50(6): 385–8PubMed

64.

Wallwork B, Coman W, Feron F, et al. Clarithromycin and prednisolone inhibit cytokine production in chronic rhinosinusitis. Laryngoscope 2002 Oct; 112(10): 1827–30PubMedCrossRef

65.

Nadel DM, Lanza DC, Kennedy DW. Endoscopically guided cultures in chronic sinusitis. Am J Rhinol 1998; 12(4): 233–41PubMedCrossRef

66.

Cervin A. The anti-inflammatory effect of erythromycin and its derivatives, with special reference to nasal polyposis and chronic sinusitis. Acta Otolaryngol 2001; 121(1): 83–92PubMedCrossRef

67.

Yamada T, Fujieda S, Mori S, et al. Macrolide treatment decreased the size of nasal polyps and IL-8 levels in nasal lavage. Am J Rhinol 2000; 14(3): 143–8PubMedCrossRef

68.

Nonaka M, Pawankar R, Tomiyama S, et al. A macrolide antibiotic, roxithromycin, inhibits the growth of nasal polyp fibroblasts. Am J Rhinol 1999; 13(4): 267–72PubMedCrossRef

69.

lino Y, Sasaki Y, Kojima C, et al. Effect of macrolides on the expression of HLA-DR and costimulatory molecules on antigen-presenting cells in nasal polyps. Ann Otol Rhinol Laryngol 2001; 110(5): 457–63

70.

Ichimura K, Shimazaki Y, Ishibashi T, et al. Effect of new macrolide roxithromycin upon nasal polyps associated with chronic sinusitis. Auris Nasus Larynx 1996; 23: 48–56PubMedCrossRef

71.

Kraft M, Cassell GH, Pak J, et al. Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest 2002; 121(6): 1782–8PubMedCrossRef

72.

Keith PK, Conway M, Evans S, et al. Nasal polyps: effects of seasonal allergen exposure. J Allergy Clin Immunol 1994; 93(3): 567–74PubMedCrossRef

73.

Crampette L, Mainprice B, Bloom M, et al. Inhibition of mediator and cytokine release from dispersed nasal polyp cells by terfenadine. Allergy 1996; 51(5): 346–9PubMed

74.

Campbell A, Michel FB, Bremard-Oury C, et al. Overview of allergic mechanisms: ebastine has more than an antihistamine effect. Drugs 1996; 52 Suppl. 1: 15–9CrossRef

75.

Carayol N, Crampette L, Mainprice B, et al. Inhibition of mediator and cytokine release from dispersed nasal polyp cells by mizolastine. Allergy 2002; 57(11): 1067–70PubMedCrossRef

76.

Kusters S, Schuligoi R, Huttenbrink KB, et al. Effects of antihistamines on leukotriene and cytokine release from dispersed nasal polyp cells. Arzneimittelforschung 2002; 52(2): 97–102PubMed

77.

Vignola AM, Crampette L, Mondain M, et al. Inhibitory activity of loratadine and descarboethoxyloratadine on expression of ICAM-1 and HLA-DR by nasal epithelial cells. Allergy 1995; 50(3): 200–3PubMedCrossRef

78.

Haye R, Aanesen JP, Burtin B, et al. The effect of cetirizine on symptoms and signs of nasal polyposis. J Laryngol Otol 1998; 112(11): 1042–6PubMedCrossRef

79.

Ogino S, Irifune M, Harada T, et al. Arachidonic acid metabolites in human nasal polyps. Acta Otolaryngol Suppl 1993; 501: 85–7CrossRef

80.

Yamashita T, Tsuji H, Maeda N, et al. Etiology of nasal polyps associated with aspirin-sensitive asthma. Rhinology 1989; 8: 15–24

81.

Steinke JW, Bradley D, Arango P, et al. Cysteinyl leukotriene expression in chronic hyperplastic sinusitis-nasal polyposis: importance to eosinophilia and asthma. J Allergy Clin Immunol 2003; 111(2): 342–9PubMedCrossRef

82.

Sousa AR, Parikh A, Scadding G, et al. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 2002; 347(19): 1493–9PubMedCrossRef

83.

Parnes SM. The role of leukotriene inhibitors in allergic rhinitis and paranasal sinusitis. Curr Allergy Asthma Rep 2002; 2(2): 239–44PubMedCrossRef

84.

Parnes SM, Chuma AV. Acute effects of antileukotrienes on sinonasal polyposis and sinusitis. Ear Nose Throat J 2000; 79(1): 18–20, 24-5PubMed

85.

Ulualp SO, Sterman BM, Toohill RJ. Antileukotriene therapy for the relief of sinus symptoms in aspirin triad disease. Ear Nose Throat J 1999; 78(8): 604–6, 608, 613PubMed

86.

Di Rienzo L, Artuso A, Cerqua N. Antileukotrienes in the prevention of postoperative recurrence of nasal polyposis in ASA syndrome. Acta Otorhinolaryngol Ital 2000; 20(5): 336–42PubMed

87.

Ragab S, Parikh A, Darby YC, et al. An open audit of montelukast, a leukotriene receptor antagonist, in nasal polyposis associated with asthma. Clin Exp Allergy 2001; 31(9): 1385–91PubMedCrossRef

88.

Stevenson DD, Hankammer MA, Mathison DA, et al. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes. J Allergy Clin Immunol 1996; 98(4): 751–8PubMedCrossRef

89.

Stevenson DD. Aspirin desensitization in patients with AERD. Clin Rev Allergy Immunol 2003; 24(2): 159–68PubMedCrossRef

90.

Gosepath J, Schafer D, Mann WJ. Aspirin sensitivity: long term follow-up after up to 3 years of adaptive desensitization using a maintenance dose of 100mg of aspirin a day. Laryngorhi-nootologie 2002 Oct; 81(10): 732–8CrossRef

91.

Levasseur-Acker GM, Molimard M, Regnard J, et al. Effect of furosemide on prostaglandin synthesis by human nasal and bronchial epithelial cells in culture. Am J Respir Cell Mol Biol 1994; 10(4): 378–83PubMed

92.

Passali D, Mezzedimi C, Passali GC, et al. Efficacy of inhalation form of furosemide to prevent postsurgical relapses of rhinosinusal polyposis. ORL J Otorhinolaryngol Relat Spec 2000; 62(6): 307–10PubMedCrossRef

93.

Bellussi L, Marchi G, Lauriello M, et al. Longitudinal study on nasal polyposis: etiopathogenetic, clinical and therapeutic aspects. Acta Otorhinolaryngol Ital 1996; 16(2): 109–13PubMed

94.

Simon HU. The neutralization of interleukin-5 as a therapeutic concept in allergic inflammation. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19(1): 25–8PubMed

95.

Tomaki M, Zhao LL, Sjostrand M, et al. Comparison of effects of anti-IL-3, IL-5 and GM-CSF treatments on eosinophilo-poiesis and airway eosinophilia induced by allergen. Pulm Pharmacol Ther 2002; 15(2): 161–8PubMedCrossRef

96.

Danzig M, Cuss F. Inhibition of interleukin-5 with a monoclonal antibody attenuates allergic inflammation. Allergy 1997; 52(8): 787–94PubMedCrossRef

97.

Liu LY, Sedgwick JB, Bates ME, et al. Decreased expression of membrane IL-5 receptor alpha on human eosinophils: I. loss of membrane IL-5 receptor alpha on airway eosinophils and increased soluble IL-5 receptor alpha in the airway after allergen challenge. J Immunol 2002; 169(11): 6452–8

98.

Gregory B, Kirchem A, Phipps S, et al. Differential regulation of human eosinophil IL-3, IL-5, and GM-CSF receptor alpha-chain expression by cytokines: IL-3, IL-5, and GM-CSF down-regulate IL-5 receptor alpha expression with loss of IL-5 responsiveness, but up-regulate IL-3 receptor alpha expression. J Immunol 2003; 170(11): 5359–66PubMed

99.

Menzies-Gow A, Flood-Page P, Sehmi R, et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil matu-rational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol 2003; 111(4): 714–9PubMedCrossRef

100.

Foster PS, Hogan SP, Yang M, et al. Interleukin-5 and eosinophils as therapeutic targets for asthma. Trends Mol Med 2002; 8(4): 162–7PubMedCrossRef

101.

Ma W, Bryce PJ, Humbles AA, et al. CCR3 is essential for skin eosinophilia and airway hyperresponsiveness in a murine model of allergic skin inflammation. J Clin Invest 2002; 109(5): 621–8PubMed

102.

Ying S, Robinson DS, Meng Q, et al. Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma: association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells. Eur J Immunol 1997; 27(12): 3507–16PubMedCrossRef

103.

Stellate C, Brummet ME, Plitt JR, et al. Expression of the C-C chemokine receptor CCR3 in human airway epithelial cells. J Immunol 2001; 166(3): 1457–61

104.

Kato Y, Fujisawa T, Shibano M, et al. Airway epithelial cells promote transmigration of eosinophils in a new three-dimensional chemotaxis model. Clin Exp Allergy 2002; 32(6): 889–97PubMedCrossRef

105.

Saito H, Shimizu H, Akiyama K. Autocrine regulation of eotaxin in normal human bronchial epithelial cells. Int Arch Allergy Immunol 2000; 122 Suppl. 1: 50–3CrossRef

106.

Taylor-Clark T, Salagean EM, Salib R, et al. The influence of intranasal pre-treatment with anti)eotaxin monoclonal antibody, CAT-213, on the nasal response to allergen challenge in rhinitis [abstract]. Allergy 2003; 58 Suppl. 74: 6

107.

White JR, Lee JM, Dede K, et al. Identification of potent, selective non-peptide CC chemokine receptor-3 antagonist that inhibits eotaxin-, eotaxin-2-, and monocyte chemotactic proteins-induced eosinophil migration. J Biol Chem 2000; 275(47): 36626–31PubMedCrossRef

108.

Sempowski GD, Beckmann MP, Derdak S, et al. Subsets of murine lung fibroblasts express membrane-bound and soluble IL-4 receptors: role of IL-4 in enhancing fibroblast proliferation and collagen synthesis. J Immunol 1994; 152(7): 3606–14PubMed

109.

Hamilos DL, Thaw ley SE, Kramper MA, et al. Effect of intranasal fluticasone on cellular infiltration, endothelial adhesion molecule expression, and proinflammatory cytokine mRNA in nasal polyp disease. J Allergy Clin Immunol 1999; 103(1): 79–87PubMedCrossRef

110.

Min YG, Lee CH, Rhee CS, et al. Inflammatory cytokine expression on nasal polyps developed in allergic and infectious rhinitis. Acta Otolaryngol 1997; 117(2): 302–6PubMedCrossRef

111.

Borish LC, Nelson HS, Corren J, et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma: IL-4R Asthma Study Group. J Allergy Clin Immunol 2001; 107(6): 963–70PubMedCrossRef

112.

Hahn C, Teufel M, Herz U, et al. Inhibition of the IL-4/IL-13 receptor system prevents allergic sensitization without affecting established allergy in a mouse model for allergic asthma. J Allergy Clin Immunol 2003; 111(6): 1361–9PubMedCrossRef

113.

Tomkinson A, Duez C, Cieslewicz G, et al. A murine IL-4 receptor antagonist that inhibits IL-4- and IL-13-induced responses prevents antigen-induced airway eosinophilia and airway hyperresponsiveness. J Immunol 2001; 166(9): 5792–800PubMed

114.

Noga O, Hanf G, Kunkel G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol 2003; 131(1): 46–52PubMedCrossRef

115.

Corren J, Casale T, Deniz Y, et al. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol 2003; 111(1): 87–90PubMedCrossRef

116.

Johansson SG, Haahtela T, O’Byrne PM. Omalizumab and the immune system: an overview of preclinical and clinical data. Ann Allergy Asthma Immunol 2002; 89(2): 132–8PubMedCrossRef

117.

Finn A, Gross G, van Bavel J, et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol 2003; 111(2): 278–84PubMedCrossRef

118.

Adelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000; 106(2): 253–9PubMedCrossRef

119.

Casale TB, Condemi J, LaForce C, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 2001; 286(23): 2956–67PubMedCrossRef

120.

Eckstein JW, Fung J. A new class of cyclosporin analogues for the treatment of asthma. Expert Opin Investig Drugs 2003; 12(4): 647–53PubMedCrossRef

121.

Powell N, Till S, Bungre J, et al. The immunomodulatory drugs cyclosporin A, mycophenolate mofetil, and sirolimus (rapamycin) inhibit allergen-induced proliferation and IL-5 production by PBMCs from atopic asthmatic patients. J Allergy Clin Immunol 2001; 108(6): 915–7PubMedCrossRef

122.

Evans DJ, Cullinan P, Geddes DM. Cyclosporin as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev 2001; (2): CD002993

123.

Lebel B, Crampette L, Vergnes C, et al. Inhibition of mediator release from dispersed nasal polyp cells by cyclosporin A. Int Arch Allergy Immunol 1998; 116(4): 284–7PubMedCrossRef

124.

Lechapt-Zalcman E, Coste A, d’Ortho MP, et al. Increased expression of matrix metalloproteinase-9 in nasal polyps. J Pathol 2001; 193(2): 233–41PubMedCrossRef

125.

Chandrasekar N, Jasti S, Alfred-Yung WK, et al. Modulation of endothelial cell morphogenesis in vitro by MMP-9 during glial-endothelial cell interactions. Clin Exp Metastasis 2000; 18(4): 337–42PubMedCrossRef

126.

Hanemaaijer R, Visser H, Koolwijk P, et al. Inhibition of MMP synthesis by doxycycline and chemically modified tetracyclines (CMTs) in human endothelial cells. Adv Dent Res 1998; 12(2): 114–8PubMedCrossRef

127.

Baxter BT, Pearce WH, Waltke EA, et al. Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (phase II) multicenter study. J Vasc Surg 2002; 36(1): 1–12PubMedCrossRef

Title: Pharmacological Management of Nasal Polyposis
Authors: Prof. Dr Claus Bachert
Jean-Baptiste Watelet
Philippe Gevaert
Paul Van Cauwenberge
Publication date: 01-08-2005
Publisher: Springer International Publishing
Published in: Drugs / Issue 11/2005
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200565110-00006

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Pharmacological Management of Nasal Polyposis

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2005

Posaconazole

Impact of Smoking on Asthma Therapy

Posaconazole

Rosiglitazone/Metformin

Immunological Aetiology of Major Psychiatric Disorders

Pegaptanib